Cytek Biosciences (CTKB) Total Current Liabilities (2020 - 2026)

Cytek Biosciences has reported Total Current Liabilities for 7 years, with the latest figure at $80.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 19.57% year-over-year to $80.9 million; the trailing twelve-month figure through Mar 2026 stood at $80.9 million (up 19.57% YoY), and the FY2025 full-year result was $77.8 million, up 14.99% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $80.9 million, up from $77.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $80.9 million in Q1 2026, with the low at $41.5 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $59.6 million across 5 years, with a median of $56.5 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 50.36% — and 2024, when it fell 2.26%.
• Cytek Biosciences' Total Current Liabilities stood at $49.0 million in 2022, then climbed by 14.65% to $56.2 million in 2023, then rose by 20.34% to $67.7 million in 2024, then rose by 14.99% to $77.8 million in 2025, then grew by 4.02% to $80.9 million in 2026.
• The last three Total Current Liabilities figures came in at $80.9 million (Q1 2026), $77.8 million (Q4 2025), and $75.2 million (Q3 2025), per Business Quant data.